Jefferies Upgrades Vanda Pharmaceuticals (VNDA) to Buy; Giving Credit for Tasimelteon
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 1c
February 12, 2013 7:31 AM ESTVanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q4 EPS of ($0.23), $0.01 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $7.9 million versus the consensus estimate of $8.6 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.... More
